Gefitinib Treatment in EGFR Mutated Caucasian NSCLC: Circulating-Free Tumor DNA as a Surrogate for Determination of EGFR Status

Benzer Materyaller

• First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study
  Yazar:: Douillard, J-Y, ve diğerleri
  Baskı/Yayın Bilgisi: (2014)
• JUN-Mediated downregulation of EGFR signaling is associated with resistance to gefitinib in EGFR-mutant NSCLC cell lines
  Yazar:: Kani, Kian, ve diğerleri
  Baskı/Yayın Bilgisi: (2017)
• Shikonin sensitizes wild-type EGFR NSCLC cells to erlotinib and gefitinib therapy
  Yazar:: Li, Yang-Ling, ve diğerleri
  Baskı/Yayın Bilgisi: (2018)
• Capmatinib and gefitinib combination therapy: will EGFR-mutated MET-dysregulated NSCLC “capitulate”?
  Yazar:: Ko, Brian, ve diğerleri
  Baskı/Yayın Bilgisi: (2018)
• The Dissociation of Gefitinib Trough Concentration and Clinical Outcome in NSCLC Patients with EGFR Sensitive Mutations
  Yazar:: Xin, Shuang, ve diğerleri
  Baskı/Yayın Bilgisi: (2015)